6 questions answered from cited research · Plain language
Some inherited gene mutations can raise the risk of both paraganglioma and thyroid cancer, but the sources do not show that paraganglioma directly causes thyroid cancer lymph node spread.
Read the full answer →Yes, the Systemic Immune-Inflammation Index (SII) can help predict lymph node metastasis in thyroid cancer, with studies showing moderate diagnostic accuracy.
Read the full answer →Yes, immune microenvironment characterization helps identify immune subtypes and biomarkers to guide precision immunotherapy in thyroid cancer, especially for aggressive forms.
Read the full answer →Yes, encorafenib plus binimetinib is effective for BRAF V600E-mutated thyroid cancer, with a 54.5% objective response rate in a phase 2 trial, including responses in both differentiated and anaplastic subtypes.
Read the full answer →Yes, the gut microbiome likely influences thyroid cancer development through immune regulation, hormone metabolism, and metabolite production, though direct evidence in humans is still limited.
Read the full answer →Yes, the Systemic Immune-Inflammation Index (SII) shows moderate diagnostic accuracy for thyroid cancer, with pooled sensitivity of 76.8% and specificity of 71.2% based on a meta-analysis.
Read the full answer →